KOTRA x Provision Consulting Group to Support Korean Companies at BIO Convention San Diego

GlowBridge
2 days ago
2 min read

The BIO International Convention, taking place in San Diego from June 22–25, is one of the world's leading events for the biotechnology and life sciences industry. Every year, the convention brings together biotechnology companies, pharmaceutical developers, investors, research institutions, manufacturers, and regulatory experts from around the globe to explore partnerships, investment opportunities, and commercialization strategies.

For companies developing innovative healthcare products, BIO offers a unique opportunity to connect with key stakeholders across the life sciences ecosystem and gain valuable insights into the U.S. market.

Who Can Benefit from BIO Convention?

BIO is especially valuable for:

Biotechnology and pharmaceutical companies seeking global partnerships
Medical device and diagnostic developers exploring U.S. market opportunities
Startups looking for investment and strategic collaborations
Research institutions pursuing commercialization opportunities
Service providers supporting product development, manufacturing, and regulatory compliance

As many companies attending BIO are preparing for clinical development, commercialization, or U.S. market entry, understanding FDA requirements early in the process is becoming increasingly important.

KOTRA x Provision Consulting Group

This year, Provision Consulting Group is pleased to support Korean companies participating in BIO through collaboration with KOTRA.

During the convention, Provision will provide FDA Regulatory Triage Consultations designed to help companies better understand their potential regulatory pathway in the United States.

The consultation will focus on:

Identifying the applicable FDA regulatory category for the product
Discussing potential FDA submission pathways
Evaluating intended use statements and product claims from a regulatory perspective

These consultations are intended to provide practical, high-level regulatory guidance and help companies identify potential regulatory considerations before investing significant time and resources into U.S. market expansion.

For more complex areas—including INDs, NDAs, biologics, cell and gene therapy products, CMC requirements, and clinical trial strategy—additional technical review and regulatory assessment may be necessary. Companies requiring in-depth evaluation will be advised on appropriate next steps and follow-up consultation options.

Helping Companies Navigate the U.S. Regulatory Landscape

Successful entry into the U.S. market begins with a clear understanding of how a product may be regulated by FDA. Early identification of regulatory classification, submission requirements, and claim-related risks can help companies avoid costly delays and make more informed development decisions.

Provision Consulting Group looks forward to meeting innovative companies at BIO Convention San Diego and supporting their journey toward successful U.S. commercialization.